Journal: eLife

Article Title: Formation of retinal direction-selective circuitry initiated by starburst amacrine cell homotypic contact

doi: 10.7554/eLife.34241

Figure Lengend Snippet:

Article Snippet: Antibody , AP-2a: mouse, 1:200 , Developmental Studies Hybridoma Bank , 3B5 , .

Techniques: Plasmid Preparation, Electron Microscopy, Fluorescence, Membrane, Blocking Assay, Immunoprecipitation, Protease Inhibitor, DC Protein Assay, Recombinant, Construct, Software, Sequencing

Journal: bioRxiv

Article Title: Repression of Transcription Factor AP-2 Alpha by Peroxisome Proliferator Activated Receptor Gamma Reveals a Novel Transcriptional Circuit in basal-squamous Bladder Cancer

doi: 10.1101/401307

Figure Lengend Snippet: PPARγ activation represses TFAP2A expression in human bladder cancer cells. A: q-RT-PCR analysis of FABP4 expression levels in UMUC1, SW780 and 5637 cells after 48 hours PPARγ agonist treatment. FABP4 expression was normalized by GAPDH, internal control. * p<0.05, ** p<0.01, (Student’s t test). B: q-RT-PCR analysis of TFAP2A expression levels in UMUC1, SW780 and 5637 cells after 48 hours PPARγ agonist treatment. TFAP2A expression was normalized by GAPDH, internal control. ** p<0.01, **** p<0.0001 (Student’s t test). C: Western blot analysis of TFAP2A protein expression level in UMUC1, SW780, 5637 cells after 48 hours PPARγ agonist treatment. Densitometric analysis of western blot of TFAP2A expression (below). * p<0.05 (Student’s t test). In A, B, C relative expression levels of FABP4 and TFAP2A mRNA and or/protein after PPARγ agonist treatment are represented compared to that of DMSO treatment.

Article Snippet: TFAP2A (Hs01029413_m1), TFAP2C (Hs00231476_m1), FABP4 (Hs01086177_m1).

Techniques: Activation Assay, Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot

Journal: bioRxiv

Article Title: Repression of Transcription Factor AP-2 Alpha by Peroxisome Proliferator Activated Receptor Gamma Reveals a Novel Transcriptional Circuit in basal-squamous Bladder Cancer

doi: 10.1101/401307

Figure Lengend Snippet: Repression of TFAP2A expression via PPARγ is dependent on a functional receptor. A and B: q-RT-PCR analysis of FABP4 (A) and TFAP2A (B) expression levels in UMUC1, SW780 and 5637 cells after PPARγ agonist (1μM) treatment alone or in the presence of the PPARγ antagonist (5 μM), GW9662. The putative PPARγ-regulated gene, FABP4 was used as positive control for drug treatments. Relative expression levels of TFAP2A and FABP4 after PPARγ treatment is represented relative to that of DMSO treatment. ** p<0.01, *** p<0.001, ns: not significant, one-way ANOVA with post hoc multiple comparison (Tukey). C: Western blotting analysis of TFAP2A protein expression levels in UMUC1, SW780 and 5637 cells after PPARγ agonist (1μM) treatment alone and in the presence (1μM and 5μM) of the PPARγ antagonist, GW9662. Densitometric analysis of western blotting of TFAP2A expression (below). TFAP2A expression was normalized by GAPDH, internal control. * p<0.05, ** p<0.01, one-way ANOVA with post hoc multiple comparison (Tukey).

Article Snippet: TFAP2A (Hs01029413_m1), TFAP2C (Hs00231476_m1), FABP4 (Hs01086177_m1).

Techniques: Expressing, Functional Assay, Reverse Transcription Polymerase Chain Reaction, Positive Control, Western Blot

Journal: bioRxiv

Article Title: Repression of Transcription Factor AP-2 Alpha by Peroxisome Proliferator Activated Receptor Gamma Reveals a Novel Transcriptional Circuit in basal-squamous Bladder Cancer

doi: 10.1101/401307

Figure Lengend Snippet: TFAP2A and TFAP2C are highly expressed in basal-squamous bladder cancer cell lines. A-C: q-RT-PCR analysis of mRNA expression of PPARγ (A), TFAP2A (B) and TFAP2C (C) in 10 human BC cell lines. ** p<0.01, ns: not significant, Wilcoxon rank sum test. D: Western blot analysis of TFAP2A, TFAP2C and PPARγ protein expression in 10 human BC cell lines. (luminal: RT4, SW780, UMUC1/ Non-type: UMUC3, T24, TCCSup/ Basal: SCaBER, 5637, HT1376, HT1197). Densitometric analysis of western blotting data is below. TFAP2A, TFAP2C and PPARγ expression was normalized by GAPDH, internal control.

Article Snippet: TFAP2A (Hs01029413_m1), TFAP2C (Hs00231476_m1), FABP4 (Hs01086177_m1).

Techniques: Reverse Transcription Polymerase Chain Reaction, Expressing, Western Blot

Journal: bioRxiv

Article Title: Repression of Transcription Factor AP-2 Alpha by Peroxisome Proliferator Activated Receptor Gamma Reveals a Novel Transcriptional Circuit in basal-squamous Bladder Cancer

doi: 10.1101/401307

Figure Lengend Snippet: TFAP2A and TFAP2C expression is associated with basal-squamous human bladder cancer. A and B: Relationship between molecular subtype and expression of TFAP2A and TFAP2C was examined using data compiled through the TCGA bladder cancer study . While TFAP2A (A; Kruskal-Wallis H test; p <0.0001) expression was significantly elevated in the basal-squamous molecular subtype, TFAP2C (B) expression was not significantly associated with any subtype at the mRNA level. C: Hierarchical clustering analysis using data compiled through the same TCGA bladder cancer study shows tumors that express TFAP2A and TFAP2C cluster with tumors expressing additional markers of basal bladder cancer. D-M: Representative images of H&E (D, I) and IHC staining for TFAP2A (E, F, J, and K), TFAP2C (G, H, L, and M) from human BC specimens (D-H: SqD, UCC: I-M). N : TFAP2A (p<0.001; Wilcoxon rank sum) and TFAP2C (P<0.05; Wilcoxon rank sum) protein expression are significantly higher in SqD compared to UCC.

Article Snippet: TFAP2A (Hs01029413_m1), TFAP2C (Hs00231476_m1), FABP4 (Hs01086177_m1).

Techniques: Expressing, Immunohistochemistry

Journal: bioRxiv

Article Title: Repression of Transcription Factor AP-2 Alpha by Peroxisome Proliferator Activated Receptor Gamma Reveals a Novel Transcriptional Circuit in basal-squamous Bladder Cancer

doi: 10.1101/401307

Figure Lengend Snippet: Expression of TFAP2A and TFAP2C influences BC cell migration and invasion. A: Western blotting analysis of TFAP2A and TFAP2C expression in SCaBER cells after siRNA transfection. SiRNAs included Scrambled (negative control), as well as constructs targeting TFAP2A and TFAP2C individually and in combination. B: Densitometric analysis of western blotting results for TFAP2A and TFAP2C expression for data depicted in (A). TFAP2A and TFAP2C expression was normalized to GAPDH. C: Representative images following migration and Invasion assays using SCaBER cells transfected with siRNA for Scrambled construct, TFAP2A, TFAP2C, and TFAP2A/TFAP2C. D: Relative migration and invasion of SCaBER cells transfected with siRNA. *** p<0.001, **** p<0.0001, one-way ANOVA with post hoc multiple comparison (Tukey). E: Western blotting analysis of TFAP2A and TFAP2C protein expression levels in UMUC3 cells overexpressing TFAP2A (left) or TFAP2C (right). Also included is densitometric analysis of western blotting data for TFAP2A and TFAP2C. F: q-RT-PCR analysis of TFAP2A and TFAP2C expression in UMUC3 cells overexpressing TFAP2A and TFAP2C. G: Migration and Invasion assay of UMUC3 stable cells overexpressing TFAP2A. H: Migration and Invasion assay of UMUC3 cell overexpressing TFAP2C. ** p<0.01(Student’s t test).

Article Snippet: TFAP2A (Hs01029413_m1), TFAP2C (Hs00231476_m1), FABP4 (Hs01086177_m1).

Techniques: Expressing, Migration, Western Blot, Transfection, Negative Control, Construct, Reverse Transcription Polymerase Chain Reaction, Invasion Assay

Journal: bioRxiv

Article Title: Repression of Transcription Factor AP-2 Alpha by Peroxisome Proliferator Activated Receptor Gamma Reveals a Novel Transcriptional Circuit in basal-squamous Bladder Cancer

doi: 10.1101/401307

Figure Lengend Snippet: Overexpression of TFAP2A or TFAP2C in bladder cancer cell promotes tumorigenicity in tissue recombination xenografting assays. Following genetic manipulation and recombination with embryonic rat bladder mesenchyme, tissue recombinants were inserted underneath the renal capsule as described in materials and methods. (A-D) Hematoxylin and eosin staining of T24 cells engineered to stably express empty vector (A) or TFAP2A (B), empty vector (C) or TFAP2C (D) . (E-H) Hematoxylin and eosin staining of UMUC3 cells engineered to stably express empty vector (A) or TFAP2A (B) , empty vector (C) or TFAP2C (D). Overexpression of TFAP2A in T24 had no significant effect on tumor volume in the tissue recombination assay (I) , while overexpression of TFAP2C significantly increased tumor volume of T24 recombinants (J). Overexpression of TFAP2A (K) and TFAP2C (L) significantly increased tumor volume of UMUC3 recombinants. *p<0.05, ** p<0.01, ns: not significant, Wilcoxon rank-sum test.

Article Snippet: TFAP2A (Hs01029413_m1), TFAP2C (Hs00231476_m1), FABP4 (Hs01086177_m1).

Techniques: Over Expression, Staining, Stable Transfection, Plasmid Preparation, Recombination Assay

Journal: Cancer cell international

Article Title: Polymorphism rs2327430 in TCF21 predicts the risk and prognosis of gastric cancer by affecting the binding between TFAP2A and TCF21.

doi: 10.1186/s12935-024-03343-z

Figure Lengend Snippet: Fig. 3 The C allele of rs2327430 played a role in GC by blocking the binding of TFAP2A to the TCF21 promoter. Notes: (A and B) The potential of the bind ing between tagSNPs and transcription factor was analyzed and displayed according to the JASPAR database. (C) Correlation analysis between TFAP2A and TCF21 mRNA was performed in 120 GC patients and analyzed with Spearman’s correlation test. (D) Schematic illustration of the reporter gene con taining rs2327430 C or T allele constructs and reporter plasmids with the different alleles of rs2327430 were transfected into AGS and MKN45 cells. Then, the results were expressed as relative luciferase activity (Firefly luciferase/Renilla luciferase). Both cells were also co-transfected with TFAP2A plasmid, re spectively. (E) CHIP assay evaluated by qRT-PCR was performed with control IgG or antibody against TFAP2A in the AGS and MKN45 cells, results of which are normalized to the input group and shown as means ± SEM in 3 independent experiments. (F and G) The knock-down efficiency of siRNAs on TCF21 and TFAP2A was determined by qRT-PCR and western blots, respectively. (H) The rescue experiment was carried out to verify whether the expression of TCF21 is affected by TFAP2A through qRT-PCR and western blot. (I–N) It is shown that TCF21 knockdown could partially rescue functional phenotypes caused by TFAP2A knockdown including proliferation, invasion, metastasis, and apoptosis. (O) The effect of TFAP2A knockdown on AKT/Bcl-xL signaling pathway could be rescued partially by TCF21 knockdown. (P) Images of the subcutaneous xenografts were presented. tumor growth curves were drawn and the tumor weight was calculated. (Q) IHC was used to examine the expression of TCF21 and Ki67 in xenografts

Article Snippet: Broadly, we sonicated the cross-linked chromatin DNA into 200–1000 bp fragments that were immunoprecipitated with an anti-TFAP2A antibody (Proteintech, China), while normal rabbit IgG was used as the reference group.

Techniques: Blocking Assay, Binding Assay, Construct, Transfection, Luciferase, Activity Assay, Plasmid Preparation, Quantitative RT-PCR, Control, Knockdown, Western Blot, Expressing, Functional Assay

Journal: Cancer cell international

Article Title: Polymorphism rs2327430 in TCF21 predicts the risk and prognosis of gastric cancer by affecting the binding between TFAP2A and TCF21.

doi: 10.1186/s12935-024-03343-z

Figure Lengend Snippet: Fig. 4 The role of rs2327430 in modulating gastric cancer. Notes: The allele C played a protective role in gastric cancer development by inhibiting the binding with TFAP2A

Article Snippet: Broadly, we sonicated the cross-linked chromatin DNA into 200–1000 bp fragments that were immunoprecipitated with an anti-TFAP2A antibody (Proteintech, China), while normal rabbit IgG was used as the reference group.

Techniques: Binding Assay